Tianjin Beroni Biotechnology Co., Ltd, China was established. Its main business is the development and sale of healthcare related products.
12 May 2017 ●
Beroni was admitted to the NSX (Australia), raising approximately A$4.8 million.
Early 2018 ●
In early 2018, Beroni established a precision medicine R&D centre with Nankai University.
28 March 2018 ●
Beroni acquired 2.2% of Cystemix Pty Ltd upon signing a term sheet with NewSouth Innovations Pty Ltd (NSI), a subsidiary of the University of New South Wales (UNSW) to fund the clinical development of PENAO, an anti-cancer drug.
23 April 2018 ●
Beroni acquired a 51% interest in Beroni Japan.
20 June 2018 ●
Beroni entered into an agreement to acquire 100% of Medicine Plus Co. Ltd.
24 September 2018 ●
Beroni was removed from trading on FSE due to the NSX no longer being recognised by the FSE as an Approved Stock Exchange.
29 April 2019 ●
Beroni Group Ltd. began trading on OTCQX Market.
● 17 June 2016
Beroni Group (“Beroni”) was incorporated in Australia.
● 19 January 2018
Beroni was admitted to the Open Market Quotation Board of the Frankfurt Stock Exchange.
● 26 March 2018
Beroni invested US$1 million by way of a research funding agreement with Columbia University (New York) for a 12-month research program in the field of ArboViroPlex rRT-PCR Test.
● 9 April 2018
Beroni invested $2.435 million for a 17.92% interest in the Japanese cell therapy company, Dendrix Inc.
● 18 June 2018
Beroni invested JPY100 million (approx. A$1.2 million) into a capital fund, Youtokukai Foundation, to fund the establishment and development of the Tokyo Ginza International Medical Clinic in Japan.
● 21 August 2018
Beroni entered into a strategic partnership agreement with I’rom Group Co., Ltd, a company listed on the Tokyo Stock Exchange, to share resources with respect to genetic medicine and stem cell engineering.
● 9 November 2018
Beroni USA was set up with Beroni owning 100% of its shares.